Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
By John M. L. Ebos, R. Kerbel. Nature Reviews Clinical Oncology, 2011
695 citations recorded by the source corpus.
Antiangiogenic drugs targeting the VEGF pathway have slowed metastatic disease progression in some patients, leading to progression-free survival (PFS) and overall survival benefits compared with controls. However, the results are more modest than predicted by most preclinical testing and benefits in PFS are frequently not accompanied by overall survival improvements. Questions have emerged about the basis of drug resistance and the limitations of predictive preclinical models, and also about whether the nature of disease progression following antiangiogenic therapy is different to classic cytotoxic therapies—in particular whether therapy may lead to more invasive or metastatic behavior. In addition, because of recent clinical trial failures of antiangiogenic therapy in patients with early-stage disease, and the fact that there are hundreds of trials underway in perioperative neoadjuvant and adjuvant settings, there is now greater awareness about the lack of appropriate preclinical testing that preceded these studies. Improved preclinical assessment of all stages of metastatic disease should be a priority for future antiangiogenic drug discovery and development.
Subfields: Hepatology, Molecular Biology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/0464f04c127ae23b912512caea45eb25c18bd6cf
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions (2014, background): “rapid tumour progression in individuals with mRCC after withdrawing anti-angiogenic therapy, a phenomenon sometimes referred to as ‘flare-up’ [54, 89, 90, 206].”
- Angiogenic signaling pathways and anti-angiogenic therapy for cancer (2023, background): “Up to now, although a significant number of research has been devoted to anti-cancer therapy to overcome this incurable and lethal disease, none of them has achieved persistent clinical efficacy.(27,28) For example, chemotherapy is a form of systemic treatment, which has been utilized for the treatm”
- Tumor angiogenesis and vascular normalization: alternative therapeutic targets (2017, background): “increased tumor hypoxia and favor the selection of invasive tumor cells, enhancing the risks of metastatic spread [106, 107].”
- Basic and therapeutic aspects of angiogenesis. (2011, neutral): “, 2008), and large meta-analyses have not shown a worse clinical outcome (Ebos and Kerbel, 2011; Miles et al., 2011).”
- Accessories to the crime: functions of cells recruited to the tumor microenvironment. (2012, neutral): “…of proangiogenic IICs or CAFs (Priceman et al., 2010; Shojaei et al., 2007), and in others shifting to heightened dependence on invasion and metastasis to co-opt normal tissue vasculature instead of producing a neovasculature (Ebos and Kerbel, 2011; Pà ez-Ribes et al., 2009; Sennino et al., 2012).”